Faculty profile

Barbara Vanderhyden

Back to faculty

Distinguished ProfessorCellular and Molecular MedicineUniversity of Ottawa

Barbara Vanderhyden

Distinguished Professor

Cellular and Molecular Medicine

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
11 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 17 research grants (11 CIHR, 6 NSERC), most recently in 2022.
Supervisor on 8 trainee awards (8 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Ovarian Cancer Cytokines Cytotoxic T Lymphocytes Immune Surveillance Immune System Response Nlrc5 Immunotherapy Brca1

Latest papers

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.
Molecular therapy : the journal of the American Society of Gene Therapy · 2026
Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.
Gynecologic oncology · 2026
MRI of combination immunotherapy in an epithelial ovarian cancer preclinical model.
Npj imaging · 2026

All 26 publications

Latest funding

Harnessing IL-33 and Checkpoint Blockade to Boost Adaptive Immunity in Ovarian Cancer
CIHR · 2025 · Supervisor
$120,000
HLA-mediated epitype-immune interactions in high-grade serous ovarian cancer
CIHR · 2025 · Supervisor
$140,000
Harnessing ILC2 for immunotherapy of ovarian cancer.
CIHR · 2024 · Co-investigator
$1,005,975

All 29 grants and awards

26 publications.

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Viens M, Geoffroy K, Meuriot E, Buccilli A, Mullins-Dansereau V, Myre ML, Paradisis S, Bardoul A, Kalin EM, Saraiva BA, Valencia J, Leclerc Desaulniers K, Hoang HD, Hassan S, Bell JC, Vanderhyden B, Alain T, Roy DG, Cook DP, Bourgeois-Daigneault MC

Molecular therapy : the journal of the American Society of Gene Therapy2026

DOI: 10.1016/j.ymthe.2026.04.061 PMID: 42093158

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

Grube M, Ribeiro de Souza B, Neilson A, Tinker A, Staebler A, Kuzma T, Nelson GS, de Kroon C, Bosse T, Kroep JR, Teo-Fortin LA, Bachvarov D, Brummel K, de Bruyn M, Nijman H, Andres S, Schochter F, Fink A, Moubarak M, Heitz F, Harter P, Bartl T, Grimm C, Hofstetter G, Sideris M, Manchanda R, Heublein S, Fischer-Straub A, Kommoss FKF, Kulkarni A, Vanderhyden B, Knoll K, Zeimet A, Wimberger P, Link T, Jaeger A, Schmalfeldt B, Lampe B, Yasmeen A, Phouthavongsy L, Vollert HW, Lycke M, Mateoiu CC, Irving J, Watson P, Nachtigal M, de Ladurantaye M, van de Laar E, Plante M, Kommoss F, Talhouk A, Koebel M, Anglesio MS, Kommoss S

Gynecologic oncology2026

DOI: 10.1016/j.ygyno.2026.04.008 PMID: 42090883

MRI of combination immunotherapy in an epithelial ovarian cancer preclinical model.

Gosse JT, Skelton CS, Tremblay ML, Wyatt H, Gonzalez V, Dawod B, Nuschke A, Davis C, Dirk B, Vila-Leahey A, Mackay A, Bobbitt K, West A, Vanderhyden B, Weir G, Merkx-Jacques A, Stanford M, Hrytsenko O, Brewer KD

Npj imaging2026

DOI: 10.1038/s44303-026-00157-8 PMID: 41957244

Doxorubicin enhances adipogenesis in an FGF2-dependent manner and induces a tumour-promoting secretory phenotype.

Kreps LM, Yakubovich E, Zhao H, Yimer S, Yang E, Cruz J, Vanderhyden B, Addison CL

Journal of bone oncology2026

DOI: 10.1016/j.jbo.2026.100754 PMID: 41777792

ILC2s in cancer: good, bad, or stay tuned?

Asif S, Kinzel M, Vanderhyden B, Jacquelot N, Ardolino M

Trends in molecular medicine2026

DOI: 10.1016/j.molmed.2025.06.010 PMID: 40651913

Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression.

Zhu Y, Abedini A, Rodriguez GM, McCloskey CW, Abou-Hamad J, Salah OS, Larocque J, Tsoi MF, Boerboom D, Cook D, Vanderhyden B

Oncogene2025Senior author

DOI: 10.1038/s41388-025-03387-z PMID: 40221530

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.

Wong B, Bergeron A, Maznyi G, Ng K, Jirovec A, Birdi HK, Serrano D, Spinelli M, Thomson M, Taha Z, Alwithenani A, Chen A, Lorimer I, Vanderhyden B, Arulanandam R, Diallo JS

Molecular therapy : the journal of the American Society of Gene Therapy2023

DOI: 10.1016/j.ymthe.2023.09.017 PMID: 37766429

Androgen-induced exosomal miR-379-5p release determines granulosa cell fate: cellular mechanism involved in polycystic ovaries.

Salehi R, Wyse BA, Asare-Werehene M, Esfandiarinezhad F, Abedini A, Pan B, Urata Y, Gutsol A, Vinas JL, Jahangiri S, Xue K, Xue Y, Burns KD, Vanderhyden B, Li J, Osuga Y, Burger D, Tan SL, Librach CL, Tsang BK

Journal of ovarian research2023

DOI: 10.1186/s13048-023-01141-1 PMID: 37046285

Granulosa cell-derived miR-379-5p regulates macrophage polarization in polycystic ovarian syndrome.

Salehi R, Asare-Werehene M, Wyse BA, Abedini A, Pan B, Gutsol A, Jahangiri S, Szaraz P, Burns KD, Vanderhyden B, Li J, Burger D, Librach CL, Tsang BK

Frontiers in immunology2023

DOI: 10.3389/fimmu.2023.1104550 PMID: 37033997

Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment.

Surendran A, Jamalkhah M, Poutou J, Birtch R, Lawson C, Dave J, Crupi MJF, Mayer J, Taylor V, Petryk J, de Souza CT, Moodie N, Billingsley JL, Austin B, Cormack N, Blamey N, Rezaei R, McCloskey CW, Fekete EEF, Birdi HK, Neault S, Jamieson TR, Wylie B, Tucker S, Azad T, Vanderhyden B, Tai LH, Bell JC, Ilkow CS

Frontiers in immunology2023

DOI: 10.3389/fimmu.2023.1099459 PMID: 36969187

Harnessing IL-33 and Checkpoint Blockade to Boost Adaptive Immunity in Ovarian Cancer

SupervisorCIHR2025DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Principal investigators: Ibrahim, Dalia K

Keywords: Checkpoint Blockade; Immune System; Immunotherapy; Mouse Models; Ovarian Cancer; Spatial Transcriptomics; Tumor Microenvironment

$120,000

HLA-mediated epitype-immune interactions in high-grade serous ovarian cancer

SupervisorCIHR2025Canada Postdoctoral Research Award (CPRA) program

Principal investigators: Nersesian, Sarah

Keywords: Cancer Immunotherapy; Hla Regulation; Immune Evasion; Immune Microenvironment; Multiple Immunofluorescence; Ovarian Cancer; Single-Cell Transcriptomics; Spatial Transcriptomics; Tumour Heterogeneity; Tumour-Immune Interactions

$140,000

Harnessing ILC2 for immunotherapy of ovarian cancer.

Co-investigatorCIHR2024Project Grant

Principal investigators: Ardolino, Michele

Keywords: Immunotherapy; Innate Immunity; Innate Lymphoid Cells; Oncolytic Viruses; Ovarian Cancer; Tumor Immunology

$1,005,975

The Effect of BRCA Mutation and Metformin Use on Premature Ovarian Aging

SupervisorCIHR2023Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Murray, Alyssa

Keywords: Age; Brca Mutation; Chemoprevention; Fibroblast Hyperactivity; Fibrosis; Inflammation; Metformin; Ovarian Cancer Risk; Ovary; Transcriptomics

$105,000

Not just an army: the role of innate lymphoid cells in mammalian ovulation

SupervisorCIHR2022Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Asif, Sara

Keywords: Cytokine; Female Reproductive System; Immunology; Inflammation; Innate Lymphoid Cells; Natural Killer Cells; Ovarian Cancer; Single-Cell Transcriptomics; Women'S Health

$105,000

Increasing anti-tumoral responses to ovarian cancer using engineered viruses

Nominated PICIHR2022Project Grant

Principal investigators: Vanderhyden, Barbara C

Keywords: Cytokines; Cytotoxic T Lymphocytes; Immune Surveillance; Immune System Response; Immunopeptidome; Immunotherapy; Mhc I; Nlrc5; Oncolytic Virus; Ovarian Cancer

$906,525

Replacement of a high-throughput long-term live-cell analysis instrument

Co-investigatorNSERC2022Research Tools and Instruments

Principal investigators: Côté, Marceline

$150,000

Proteomic characterization of molecular pathways at the single-cell level in human heterogeneous systems

Co-investigatorNSERC2022Research Tools and Instruments

Principal investigators: Benoit, Yannick

$112,820

Reducing ovarian cancer risk by regulating age-associated ovarian fibrosis

Nominated PICIHR2020Project Grant

Principal investigators: Vanderhyden, Barbara C

Keywords: Age; Brca Mutation; Chemoprevention; Fibroblast Hyperactivity; Fibrosis; Gliptin; Inflammation; Metformin; Ovarian Cancer Risk; Ovary

$680,850

2020 Canadian Conference on Ovarian Cancer Research: Intensity Innovation, Improve Impact

Nominated PICIHR2019Planning and Dissemination Grant - Institute Community Support

Principal investigators: Vanderhyden, Barbara C

Keywords: Genetic Susceptibility; Genome Dynamics; Immunotherapy; Mechanisms Of Metastasis; Model Systems; Ovarian Cancer; Prevention; Subtype-Specific Therapeutics; Survivors Workshop; Trainee Workshop

$10,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Barbara Vanderhyden

Research

Latest papers

Latest funding

Estrogen-mediated NF-&#x3ba;B blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

MRI of combination immunotherapy in an epithelial ovarian cancer preclinical model.

Doxorubicin enhances adipogenesis in an FGF2-dependent manner and induces a tumour-promoting secretory phenotype.

ILC2s in cancer: good, bad, or stay tuned?

Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSV&#x394;51 oncolytic virotherapy.

Androgen-induced exosomal miR-379-5p release determines granulosa cell fate: cellular mechanism involved in polycystic ovaries.

Granulosa cell-derived miR-379-5p regulates macrophage polarization in polycystic ovarian syndrome.

Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment.

Replacement of a high-throughput long-term live-cell analysis instrument

Proteomic characterization of molecular pathways at the single-cell level in human heterogeneous systems

Frequent collaborators

Jean-Simon Diallo

Dylan Burger

Tommy Alain

Anne-Marie Mes-Masson

Jerry Pelletier

Lee-Hwa Tai

Peter Watson

Michele Ardolino

Dominique Trudel

Dominique Trudel

Aline Talhouk

Anna Tinker

Marie-Claude Bourgeois-Daigneault

Morag Park

Jaahnavi Dave

Nicolas Jacquelot

David Cook

Harold Atkins

Balazs Nyiri

Laura Hopkins

Ian Lorimer

Michael Witcher

Nahum Sonenberg

David Huntsman

Derek Boerboom

Sidong Huang

Derrick Gibbings

Chantal Guillemette

Janusz Rak

Estrogen-mediated NF-κB blockade enables breast cancer sensitivity to oncolytic VSV virotherapy.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.